NEW YORK, June 8, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ProNAi Therapeutics, Inc. ("ProNAi" or the "Company") (NASDAQ: DNAI). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at email@example.com or 212-697-6484.
This investigation concerns whether ProNAi and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On June 6, 2016, ProNAi released its interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Nick Glover, President and CEO said, "Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine," the Company has "decided to suspend the development of PNT2258" because the results were not "robust enough to justify continued development of the drug in DLBCL."
Following this news, ProNAi stock dropped from a previous market close on June 3 of $6.38 per share to close at just $2.07 per share on June 6, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of ProNAi, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!dnai/zrixk. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-pronai-therapeutics-inc-dnai-300281864.html
SOURCE Bronstein, Gewirtz & Grossman, LLC